RootPath is focused on developing personalized TCR and CAR-T therapies targeting solid tumors. The company’s core product effort centers on individualized T-cell receptor and CAR-T treatments designed for patients with solid cancers. According to the article, RootPath announced an $11 million raise to support development of these personalized treatments. The report does not include operating metrics such as revenue or user numbers. Other corporate details (founding year, location, pipeline specifics) are not provided in the article. RootPath develops a personalized T cell therapy platform aimed at bridging precision medicine and cancer immunotherapy. The company is building next-generation technologies to precisely monitor, modulate and steer the immune system for cancer diagnosis and treatment. Founded in 2017 by Drs. Xi Chen, Le Cong, Yinqing Li and Ely Porter, RootPath was launched by Nest.Bio Ventures and incubated in Nest.Bio Labs in both Cambridge and Hangzhou. The company plans to use its seed proceeds to advance its immuno-oncology programs. RootPath intends to obtain key preclinical data on accuracy, efficacy and safety in animal models. Its current financial update is the $7M seed financing led by Sequoia China.

Total raised

$18M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2020